Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.4550 (4.5%) ($5.4550 - $5.4550) on Tue. Mar. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.17% (three month average) | RSI | 62 | Latest Price | $5.4550(4.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1.8% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) EMHY(34%) JNK(34%) BND(31%) HYG(28%) CEMB(32%) | Factors Impacting ADMS price | ADMS will decline at least -2.585% in a week (0% probabilities). USO(-21%) VXX(-14%) XLE(-12%) XOP(-10%) XLV(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.585% (StdDev 5.17%) | Hourly BBV | 1.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.14(6.13%) | 10 Day Moving Average | $5(9.1%) | 20 Day Moving Average | $5.13(6.34%) | To recent high | -18.1% | To recent low | 9.1% | Market Cap | $154m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |